Dr. Zhu on Primary Resistance to Osimertinib in EGFR-Mutant NSCLC OncLive 2:23 5 years ago 313 Далее Скачать
2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2 Total Health | Oncology 20:34 3 years ago 2 138 Далее Скачать
Dr. Wakelee on Rationale to Explore Osimertinib With Concurrent Chemotherapy in EGFR-Mutant NSCLC OncLive 2:03 5 years ago 183 Далее Скачать
Real world analysis of second-line osimertinib use for NSCLC in North West London VJOncology 2:11 5 years ago 317 Далее Скачать
Acquired Resistance to Osimertinib in T790M-Positive NSCLC Targeted Oncology 2:04 7 years ago 827 Далее Скачать
Dr. Padda on Overcoming Resistance to Osimertinib in EGFR+ NSCLC OncLive 1:43 5 years ago 3 335 Далее Скачать
Dr. Oxnard on Detecting Resistance Mechanisms After Treatment With Osimertinib OncLive 1:31 7 years ago 775 Далее Скачать
Dr. Yang on Resistance Mechanisms from Osimertinib in NSCLC OncLive 1:33 6 years ago 555 Далее Скачать
TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after pr... ecancer 2:30 5 years ago 270 Далее Скачать
ILCN Multidisciplinary Forum: Understanding Treatment Options and Resistance in EGFR-positive NSCLC IASLC 59:36 3 years ago 400 Далее Скачать
Osimertinib Improves Survival in EGFR+ NSCLC, Poses New Challenges for Resistance Targeted Oncology 1:15 5 years ago 600 Далее Скачать
EGFR: The Challenge of Primary and Secondary Resistance HMP Education 44:03 1 year ago 1 100 Далее Скачать
Dr. Goldberg on Options After Developing Resistance to Osimertinib for NSCLC OncLive 1:16 6 years ago 1 510 Далее Скачать
TATTON trial – Savolitinib plus osimertinib in EGFR-mutated, MET-amplified NSCLC | Lecia Sequist Medicine Matters oncology 4:49 5 years ago 383 Далее Скачать